MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the oncology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
Dr Annelies Verbiest, a medical oncologist at the University Hospital of Antwerp, has presented noteworthy findings from the mini-oral sessions on non-prostate genitourinary tumours.
Two trials investigated an intravesical drug
Mounting evidence indicates a connection between breast cancer risk and outdoor air pollution, a link previously established for lung cancer. However, establishing this association for breast cancer has been challenging
In the context of the phase 2 SWOG S1801 trial, the efficacy of neoadjuvant-adjuvant administration of pembrolizumab was compared to adjuvant treatment alone, specifically focusing on the achievement of pathological
Two clinical trials were conducted to assess the role of radiotherapy in the treatment of locally advanced rectal cancer. In the CONVERT trial, neoadjuvant chemotherapy (nCT) with CAPOX alone was
Marco Gizzi, medical oncologist working at the Grand Hôpital de Charleroi and in Clinique Universitaires Saint-Luc, Brussels, had the privilege to present the highlights on prostate cancer during the ESMO
Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp, presents a selection of key studies in the field of gynaecological cancer discussed at ESMO 2023.
A phase II dose
Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy
In the ADJORL1 study, the efficacy and safety of nivolumab were investigated as adjuvant therapy in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) following salvage surgery. All participants
MediMix is introducing “What’s New Doc in Breast Cancer?” – a weekly update on the latest research in breast cancer.
Dr Kevin Punie from GZA Ziekenhuizen, Antwerp, and Prof Evandro De Azambuja from the Jules Bordet Institute, Brussels, will provide you with detailed information on the latest data and offer you fresh insights into breast cancer treatment and research.
“What’s New Doc in Breast Cancer?” is just the beginning – it will soon expand into other domains such as GI, lung, gynaecological tumours and more. Stay tuned for a diverse range of cutting-edge communication.
